Economy/Home · Economy

ABL Bio to Present Follow-up Givastomig Data at October ESMO... Proving Competitiveness in First-Line Gastric Cancer Treatment Is Key

ABL Bio (298380) is set to present follow-up Phase 1b clinical data for Givastomig (ABL111) at the European Society for Medical Oncology (ESMO) congress in October. How well the company demonstrates competitiveness in the first-line gastric cancer treatment market is seen as a key variable for its f

Wooil Shim
Staff Reporter
7 min read
ABL Bio to Present Follow-up Givastomig Data at October ESMO... Proving Competitiveness in First-Line Gastric Cancer Treatment Is Key
CBC News

ABL Bio (298380) is set to present follow-up Phase 1b clinical data for Givastomig (ABL111) at the European Society for Medical Oncology (ESMO) congress in October. How well the company demonstrates competitiveness in the first-line gastric cancer treatment market is seen as a key variable for its future corporate value.

DS Investment Securities highlighted the following as major points of interest for ABL Bio: ▲Givastomig's clinical performance ▲the potential for segmentation of the first-line gastric cancer treatment market ▲the future development direction of ABL001.

ORR of up to 77%... Being developed in combination with nivolumab and mFOLFOX6

Givastomig is a bispecific antibody that simultaneously targets Claudin18.2 and 4-1BB. It is currently being developed as a first-line gastric cancer treatment in combination with nivolumab and the chemotherapy regimen mFOLFOX6.

In the Phase 1b trial previously disclosed by the company, the objective response rate (ORR) was 77% in the 8mg/kg dose group and 73% in the 12mg/kg dose group. The median progression-free survival (PFS) in the 8mg/kg dose group was 16.9 months.

Key question is efficacy by Claudin18.2 expression level... Focus on whether follow-up data will reconfirm it

The market is placing weight on the treatment effect according to the level of Claudin18.2 expression. Since existing data showed that the Givastomig combination therapy demonstrated relatively consistent responses regardless of PD-L1 and Claudin18.2 expression levels, the key point is whether the follow-up data to be presented at ESMO in October supports this trend.

Global Phase 2 trial underway and FDA Fast Track designation... Preparing to enter Phase 3 within the year

The development timeline is also accelerating. In February, ABL Bio and NovaRock began dosing the first patient in a global Phase 2 trial of the Givastomig combination therapy, which will evaluate PFS, ORR, and overall survival (OS) in approximately 180 patients. NovaRock has stated that it plans to present Phase 1b data at ESMO 2026.

In June, the FDA granted Fast Track designation to Givastomig as a first-line gastric cancer treatment, and the company is preparing to enter Phase 3 trials within the year.

Uncertainties remain for ABL001... "Limited share of corporate value"

In contrast, uncertainties remain for ABL001. DS Investment Securities assessed that ABL001's chances of approval have diminished after it failed to achieve statistical significance in overall survival in a bile duct cancer trial. However, the brokerage's analysis is that ABL001 accounts for a limited share of the company's total corporate value, with ABL Bio's core value lying in Givastomig, Grabody-T, and its BBB shuttle platform.

Ultimately, ABL Bio's short-term point of interest comes down to ESMO in October. If the follow-up data provides additional confirmation of durability of response, PFS, and efficacy by Claudin18.2 expression level, it is expected to influence assessments of Givastomig's competitiveness as a first-line gastric cancer treatment and its late-stage clinical trials.

Meanwhile, on the morning of the 1st, ABL Bio was trading at 71,700 won, down 1.38% from the previous trading day.

[※ This article is for informational purposes, based on securities firm reports and publicly available materials, and does not guarantee the purchase, sale, or investment returns of any specific stock. Clinical trial results and new drug development timelines of biotech companies may change or produce results different from expectations, so caution is required when making investment decisions. This article was written with AI assistance.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.